Previous close | 1,651.50 |
Open | 1,653.00 |
Bid | 1,665.00 x 0 |
Ask | 1,665.50 x 0 |
Day's range | 1,653.00 - 1,668.00 |
52-week range | 1,359.60 - 1,823.50 |
Volume | |
Avg. volume | 7,716,035 |
Market cap | 67.588B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 14.66 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.60 (3.62%) |
Ex-dividend date | 15 Aug 2024 |
1y target est | N/A |
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and in
PHILADELPHIA, August 01, 2024--Expanded approval of Jemperli (dostarlimab-gxly) plus chemo in endometrial cancer as first & only IO-based treatment to show overall survival benefit
PHILADELPHIA, July 11, 2024--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA).